Loading...
•
Dec 31, 2023
Fulgent Q4 2023 Earnings Report
Fulgent's financial performance declined in Q4 2023 due to goodwill impairment loss, but core revenue increased.
Key Takeaways
Fulgent Genetics reported a GAAP loss of $128.1 million, or $4.30 per share, but non-GAAP income of $8.3 million, or $0.28 per share. Total revenue was $70.5 million, with core revenue growing 21% year-over-year to $66.5 million. The company ended the year with $847.7 million in cash, cash equivalents, and investments.
Total revenue reached $70.5 million.
Core revenue grew 21% year-over-year to $66.5 million.
GAAP loss was $128.1 million, or $4.30 per share.
Non-GAAP income was $8.3 million, or $0.28 per share.
Revenue by Segment
Forward Guidance
For the full year 2024, Fulgent expects core revenue of approximately $280 million, GAAP loss of approximately $2.25 per share, non-GAAP loss of approximately $1.05 per share, and cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024.
Positive Outlook
- Core Revenue of approximately $280 million
Challenges Ahead
- GAAP loss of approximately $2.25 per share
- Non-GAAP loss of approximately $1.05 per share
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...